Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Revance Therapeutics

Request full access

Developing neuromodulators for the treatment of aesthetic and therapeutic conditions

Nashville, United StatesFounded 2002Biotech & Life Sciences

About Revance Therapeutics

Revance Therapeutics, Inc. is a biotechnology company that specializes in innovative aesthetic and therapeutic solutions. The company operates primarily in the aesthetics market, focusing on products that enhance physical appearance and improve patient outcomes. Revance serves a variety of clients, including healthcare professionals, aesthetic practitioners, and patients seeking minimally invasive cosmetic procedures.

Revance's product portfolio includes neuromodulators and dermal fillers, which are among the most popular minimally invasive cosmetic treatments. Neuromodulators, such as botulinum toxin type A, are used to reduce wrinkles and treat muscle movement disorders. Dermal fillers are used to restore volume and smooth out facial lines. The company is also exploring therapeutic applications for its products in treating muscle movement and pain disorders, aiming to significantly improve patient experiences.

In addition to its core product offerings, Revance has recently expanded into the financial technology (fintech) sector with the acquisition of HintMD. This platform is designed to streamline payment processes for aesthetic practices, enhancing the overall experience for both practitioners and patients. By integrating fintech solutions, Revance aims to provide a comprehensive suite of services that support the business operations of aesthetic practices.

Revance's business model is built on the development, marketing, and distribution of its innovative products. The company generates revenue through the sale of its neuromodulators and dermal fillers, as well as through its fintech platform, which offers subscription-based services to aesthetic practices. By focusing on differentiated products and improved outcomes, Revance aims to establish itself as a leader in the premium aesthetics market.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2014

Revance Therapeutics in the Nashville ecosystem

Live from Dealroom

The Revance Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

9 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

  • EW Healthcare Partners
  • Technology Partners
  • Essex Woodlands Health Ventures
  • Vivo Capital

Series B and later5 investors entered at this stage

  • Palo Alto Investors
  • Shepherd Ventures
  • Bausch Health Companies
  • NovaQuest Capital Management
  • Athyrium Capital Management
Employees mapped 777 incl. 5 AI specialists
Founders Hidden — book a demo/100 quality score
Key operators 27 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Patents

Estimated portfolio value
$40M

27 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See Revance Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.